Norway: These 44 Drugs Face Patent Expirations and Generic Entry From 2023 - 2024
DrugPatentWatch® Estimated Loss of Exclusivity Dates in Norway
The content of this page is licensed under a Creative Commons Attribution 4.0 International License.
Generic Entry Dates in Other Countries
Friedman, Yali, "Norway: These 44 Drugs Face Patent Expirations and Generic Entry From 2023 - 2024" DrugPatentWatch.com thinkBiotech, 2023 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
When can QUTENZA (capsaicin) generic drug versions launch?
Generic name: capsaicin
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 14, 2023
Generic Entry Controlled by: Norway Patent 20,055,310
QUTENZA is a drug marketed by Averitas. There are seven patents protecting this drug.
This drug has eighty-five patent family members in twenty-nine countries. There has been litigation on patents covering QUTENZA
See drug price trends for QUTENZA.
The generic ingredient in QUTENZA is capsaicin. There are six drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the capsaicin profile page.
When can QUTENZA (capsaicin) generic drug versions launch?
Generic name: capsaicin
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 14, 2023
Generic Entry Controlled by: Norway Patent 337,896
QUTENZA is a drug marketed by Averitas. There are seven patents protecting this drug.
This drug has eighty-five patent family members in twenty-nine countries. There has been litigation on patents covering QUTENZA
See drug price trends for QUTENZA.
The generic ingredient in QUTENZA is capsaicin. There are six drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the capsaicin profile page.
When can PREVYMIS (letermovir) generic drug versions launch?
Generic name: letermovir
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 02, 2023
Generic Entry Controlled by: Norway Patent 20,055,649
PREVYMIS is a drug marketed by Merck Sharp Dohme. There are three patents protecting this drug.
This drug has eighty-five patent family members in forty-five countries.
See drug price trends for PREVYMIS.
The generic ingredient in PREVYMIS is letermovir. One supplier is listed for this generic product. Additional details are available on the letermovir profile page.
When can PREVYMIS (letermovir) generic drug versions launch?
Generic name: letermovir
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 02, 2023
Generic Entry Controlled by: Norway Patent 2,018,022
PREVYMIS is a drug marketed by Merck Sharp Dohme. There are three patents protecting this drug.
This drug has eighty-five patent family members in forty-five countries.
See drug price trends for PREVYMIS.
The generic ingredient in PREVYMIS is letermovir. One supplier is listed for this generic product. Additional details are available on the letermovir profile page.
When can PREVYMIS (letermovir) generic drug versions launch?
Generic name: letermovir
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 02, 2023
Generic Entry Controlled by: Norway Patent 333,265
PREVYMIS is a drug marketed by Merck Sharp Dohme. There are three patents protecting this drug.
This drug has eighty-five patent family members in forty-five countries.
See drug price trends for PREVYMIS.
The generic ingredient in PREVYMIS is letermovir. One supplier is listed for this generic product. Additional details are available on the letermovir profile page.
When can OMONTYS (peginesatide acetate) generic drug versions launch?
Generic name: peginesatide acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 12, 2023
Generic Entry Controlled by: Norway Patent 20,055,852
OMONTYS is a drug marketed by Takeda Pharms Usa. There are six patents protecting this drug.
This drug has one hundred and fourteen patent family members in thirty-four countries.
The generic ingredient in OMONTYS is peginesatide acetate. Additional details are available on the peginesatide acetate profile page.
When can OMONTYS (peginesatide acetate) generic drug versions launch?
Generic name: peginesatide acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 12, 2023
Generic Entry Controlled by: Norway Patent 338,435
OMONTYS is a drug marketed by Takeda Pharms Usa. There are six patents protecting this drug.
This drug has one hundred and fourteen patent family members in thirty-four countries.
The generic ingredient in OMONTYS is peginesatide acetate. Additional details are available on the peginesatide acetate profile page.
When can MAYZENT (siponimod fumaric acid) generic drug versions launch?
Generic name: siponimod fumaric acid
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 19, 2023
Generic Entry Controlled by: Norway Patent 20,055,837
MAYZENT is a drug marketed by Novartis. There are two patents protecting this drug.
This drug has one hundred and forty patent family members in thirty-nine countries.
See drug price trends for MAYZENT.
The generic ingredient in MAYZENT is siponimod fumaric acid. One supplier is listed for this generic product. Additional details are available on the siponimod fumaric acid profile page.
When can MAYZENT (siponimod fumaric acid) generic drug versions launch?
Generic name: siponimod fumaric acid
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 19, 2023
Generic Entry Controlled by: Norway Patent 334,457
MAYZENT is a drug marketed by Novartis. There are two patents protecting this drug.
This drug has one hundred and forty patent family members in thirty-nine countries.
See drug price trends for MAYZENT.
The generic ingredient in MAYZENT is siponimod fumaric acid. One supplier is listed for this generic product. Additional details are available on the siponimod fumaric acid profile page.
When can JANUMET (metformin hydrochloride; sitagliptin phosphate) generic drug versions launch?
Generic name: metformin hydrochloride; sitagliptin phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 24, 2023
Generic Entry Controlled by: Norway Patent 20,060,362
This drug has one hundred and thirty-six patent family members in forty-six countries. There has been litigation on patents covering JANUMET
See drug price trends for JANUMET.
The generic ingredient in JANUMET is metformin hydrochloride; sitagliptin phosphate. There are forty-nine drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the metformin hydrochloride; sitagliptin phosphate profile page.
When can JANUMET (metformin hydrochloride; sitagliptin phosphate) generic drug versions launch?
Generic name: metformin hydrochloride; sitagliptin phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 24, 2023
Generic Entry Controlled by: Norway Patent 335,371
This drug has one hundred and thirty-six patent family members in forty-six countries. There has been litigation on patents covering JANUMET
See drug price trends for JANUMET.
The generic ingredient in JANUMET is metformin hydrochloride; sitagliptin phosphate. There are forty-nine drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the metformin hydrochloride; sitagliptin phosphate profile page.
When can JANUMET XR (metformin hydrochloride; sitagliptin phosphate) generic drug versions launch?
Generic name: metformin hydrochloride; sitagliptin phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 24, 2023
Generic Entry Controlled by: Norway Patent 20,060,362
This drug has one hundred and twenty-seven patent family members in forty-six countries. There has been litigation on patents covering JANUMET XR
See drug price trends for JANUMET XR.
The generic ingredient in JANUMET XR is metformin hydrochloride; sitagliptin phosphate. There are forty-nine drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the metformin hydrochloride; sitagliptin phosphate profile page.
When can JANUMET XR (metformin hydrochloride; sitagliptin phosphate) generic drug versions launch?
Generic name: metformin hydrochloride; sitagliptin phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 24, 2023
Generic Entry Controlled by: Norway Patent 335,371
This drug has one hundred and twenty-seven patent family members in forty-six countries. There has been litigation on patents covering JANUMET XR
See drug price trends for JANUMET XR.
The generic ingredient in JANUMET XR is metformin hydrochloride; sitagliptin phosphate. There are forty-nine drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the metformin hydrochloride; sitagliptin phosphate profile page.
When can JANUVIA (sitagliptin phosphate) generic drug versions launch?
Generic name: sitagliptin phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 24, 2023
Generic Entry Controlled by: Norway Patent 20,060,362
This drug has one hundred and twenty-seven patent family members in forty-six countries. There has been litigation on patents covering JANUVIA
See drug price trends for JANUVIA.
The generic ingredient in JANUVIA is sitagliptin phosphate. There are thirty-five drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the sitagliptin phosphate profile page.
When can JANUVIA (sitagliptin phosphate) generic drug versions launch?
Generic name: sitagliptin phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 24, 2023
Generic Entry Controlled by: Norway Patent 335,371
This drug has one hundred and twenty-seven patent family members in forty-six countries. There has been litigation on patents covering JANUVIA
See drug price trends for JANUVIA.
The generic ingredient in JANUVIA is sitagliptin phosphate. There are thirty-five drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the sitagliptin phosphate profile page.
When can JUVISYNC (simvastatin; sitagliptin phosphate) generic drug versions launch?
Generic name: simvastatin; sitagliptin phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 24, 2023
Generic Entry Controlled by: Norway Patent 20,060,362
JUVISYNC is a drug marketed by Merck Sharp Dohme. There are four patents protecting this drug and three Paragraph IV challenges.
This drug has one hundred and twenty-seven patent family members in forty-six countries. There has been litigation on patents covering JUVISYNC
The generic ingredient in JUVISYNC is simvastatin; sitagliptin phosphate. There are forty drug master file entries for this API. Additional details are available on the simvastatin; sitagliptin phosphate profile page.
When can JUVISYNC (simvastatin; sitagliptin phosphate) generic drug versions launch?
Generic name: simvastatin; sitagliptin phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 24, 2023
Generic Entry Controlled by: Norway Patent 335,371
JUVISYNC is a drug marketed by Merck Sharp Dohme. There are four patents protecting this drug and three Paragraph IV challenges.
This drug has one hundred and twenty-seven patent family members in forty-six countries. There has been litigation on patents covering JUVISYNC
The generic ingredient in JUVISYNC is simvastatin; sitagliptin phosphate. There are forty drug master file entries for this API. Additional details are available on the simvastatin; sitagliptin phosphate profile page.
When can ORIAHNN (COPACKAGED) (elagolix sodium,estradiol,norethindrone acetate; elagolix sodium) generic drug versions launch?
Generic name: elagolix sodium,estradiol,norethindrone acetate; elagolix sodium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 07, 2023
Generic Entry Controlled by: Norway Patent 20,056,251
ORIAHNN (COPACKAGED) is a drug marketed by Abbvie Inc. There are five patents protecting this drug.
This drug has thirty-eight patent family members in twenty-three countries. There has been litigation on patents covering ORIAHNN (COPACKAGED)
The generic ingredient in ORIAHNN (COPACKAGED) is elagolix sodium,estradiol,norethindrone acetate; elagolix sodium. One supplier is listed for this generic product. Additional details are available on the elagolix sodium,estradiol,norethindrone acetate; elagolix sodium profile page.
When can ORIAHNN (COPACKAGED) (elagolix sodium,estradiol,norethindrone acetate; elagolix sodium) generic drug versions launch?
Generic name: elagolix sodium,estradiol,norethindrone acetate; elagolix sodium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 07, 2023
Generic Entry Controlled by: Norway Patent 334,897
ORIAHNN (COPACKAGED) is a drug marketed by Abbvie Inc. There are five patents protecting this drug.
This drug has thirty-eight patent family members in twenty-three countries. There has been litigation on patents covering ORIAHNN (COPACKAGED)
The generic ingredient in ORIAHNN (COPACKAGED) is elagolix sodium,estradiol,norethindrone acetate; elagolix sodium. One supplier is listed for this generic product. Additional details are available on the elagolix sodium,estradiol,norethindrone acetate; elagolix sodium profile page.
When can ORILISSA (elagolix sodium) generic drug versions launch?
Generic name: elagolix sodium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 07, 2023
Generic Entry Controlled by: Norway Patent 20,056,251
This drug has forty-three patent family members in twenty-four countries. There has been litigation on patents covering ORILISSA
See drug price trends for ORILISSA.
The generic ingredient in ORILISSA is elagolix sodium. One supplier is listed for this generic product. Additional details are available on the elagolix sodium profile page.
When can ORILISSA (elagolix sodium) generic drug versions launch?
Generic name: elagolix sodium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 07, 2023
Generic Entry Controlled by: Norway Patent 334,897
This drug has forty-three patent family members in twenty-four countries. There has been litigation on patents covering ORILISSA
See drug price trends for ORILISSA.
The generic ingredient in ORILISSA is elagolix sodium. One supplier is listed for this generic product. Additional details are available on the elagolix sodium profile page.
When can VRAYLAR (cariprazine hydrochloride) generic drug versions launch?
Generic name: cariprazine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 04, 2023
Generic Entry Controlled by: Norway Patent 20,061,076
This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering VRAYLAR
See drug price trends for VRAYLAR.
The generic ingredient in VRAYLAR is cariprazine hydrochloride. There are two drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the cariprazine hydrochloride profile page.
When can VRAYLAR (cariprazine hydrochloride) generic drug versions launch?
Generic name: cariprazine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 04, 2023
Generic Entry Controlled by: Norway Patent 2,017,051
This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering VRAYLAR
See drug price trends for VRAYLAR.
The generic ingredient in VRAYLAR is cariprazine hydrochloride. There are two drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the cariprazine hydrochloride profile page.
When can VRAYLAR (cariprazine hydrochloride) generic drug versions launch?
Generic name: cariprazine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 04, 2023
Generic Entry Controlled by: Norway Patent 334,973
This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering VRAYLAR
See drug price trends for VRAYLAR.
The generic ingredient in VRAYLAR is cariprazine hydrochloride. There are two drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the cariprazine hydrochloride profile page.
When can RYZODEG 70/30 (insulin aspart; insulin degludec) generic drug versions launch?
Generic name: insulin aspart; insulin degludec
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 05, 2023
Generic Entry Controlled by: Norway Patent 20,061,026
RYZODEG 70/30 is a drug marketed by
This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering RYZODEG 70/30
The generic ingredient in RYZODEG 70/30 is insulin aspart; insulin degludec. There are forty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the insulin aspart; insulin degludec profile page.
When can RYZODEG 70/30 (insulin aspart; insulin degludec) generic drug versions launch?
Generic name: insulin aspart; insulin degludec
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 05, 2023
Generic Entry Controlled by: Norway Patent 2,018,002
RYZODEG 70/30 is a drug marketed by
This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering RYZODEG 70/30
The generic ingredient in RYZODEG 70/30 is insulin aspart; insulin degludec. There are forty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the insulin aspart; insulin degludec profile page.
When can RYZODEG 70/30 (insulin aspart; insulin degludec) generic drug versions launch?
Generic name: insulin aspart; insulin degludec
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 05, 2023
Generic Entry Controlled by: Norway Patent 2,018,003
RYZODEG 70/30 is a drug marketed by
This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering RYZODEG 70/30
The generic ingredient in RYZODEG 70/30 is insulin aspart; insulin degludec. There are forty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the insulin aspart; insulin degludec profile page.
When can RYZODEG 70/30 (insulin aspart; insulin degludec) generic drug versions launch?
Generic name: insulin aspart; insulin degludec
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 05, 2023
Generic Entry Controlled by: Norway Patent 340,925
RYZODEG 70/30 is a drug marketed by
This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering RYZODEG 70/30
The generic ingredient in RYZODEG 70/30 is insulin aspart; insulin degludec. There are forty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the insulin aspart; insulin degludec profile page.
When can TRESIBA (insulin degludec) generic drug versions launch?
Generic name: insulin degludec
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 05, 2023
Generic Entry Controlled by: Norway Patent 20,061,026
This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering TRESIBA
See drug price trends for TRESIBA.
The generic ingredient in TRESIBA is insulin degludec. There are forty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the insulin degludec profile page.
When can TRESIBA (insulin degludec) generic drug versions launch?
Generic name: insulin degludec
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 05, 2023
Generic Entry Controlled by: Norway Patent 2,018,002
This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering TRESIBA
See drug price trends for TRESIBA.
The generic ingredient in TRESIBA is insulin degludec. There are forty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the insulin degludec profile page.
When can TRESIBA (insulin degludec) generic drug versions launch?
Generic name: insulin degludec
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 05, 2023
Generic Entry Controlled by: Norway Patent 2,018,003
This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering TRESIBA
See drug price trends for TRESIBA.
The generic ingredient in TRESIBA is insulin degludec. There are forty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the insulin degludec profile page.
When can TRESIBA (insulin degludec) generic drug versions launch?
Generic name: insulin degludec
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 05, 2023
Generic Entry Controlled by: Norway Patent 340,925
This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering TRESIBA
See drug price trends for TRESIBA.
The generic ingredient in TRESIBA is insulin degludec. There are forty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the insulin degludec profile page.
When can XULTOPHY 100/3.6 (insulin degludec; liraglutide) generic drug versions launch?
Generic name: insulin degludec; liraglutide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 05, 2023
Generic Entry Controlled by: Norway Patent 20,061,026
XULTOPHY 100/3.6 is a drug marketed by
This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering XULTOPHY 100/3.6
The generic ingredient in XULTOPHY 100/3.6 is insulin degludec; liraglutide. There are forty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the insulin degludec; liraglutide profile page.
When can XULTOPHY 100/3.6 (insulin degludec; liraglutide) generic drug versions launch?
Generic name: insulin degludec; liraglutide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 05, 2023
Generic Entry Controlled by: Norway Patent 2,018,002
XULTOPHY 100/3.6 is a drug marketed by
This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering XULTOPHY 100/3.6
The generic ingredient in XULTOPHY 100/3.6 is insulin degludec; liraglutide. There are forty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the insulin degludec; liraglutide profile page.
When can XULTOPHY 100/3.6 (insulin degludec; liraglutide) generic drug versions launch?
Generic name: insulin degludec; liraglutide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 05, 2023
Generic Entry Controlled by: Norway Patent 2,018,003
XULTOPHY 100/3.6 is a drug marketed by
This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering XULTOPHY 100/3.6
The generic ingredient in XULTOPHY 100/3.6 is insulin degludec; liraglutide. There are forty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the insulin degludec; liraglutide profile page.
When can XULTOPHY 100/3.6 (insulin degludec; liraglutide) generic drug versions launch?
Generic name: insulin degludec; liraglutide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 05, 2023
Generic Entry Controlled by: Norway Patent 340,925
XULTOPHY 100/3.6 is a drug marketed by
This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering XULTOPHY 100/3.6
The generic ingredient in XULTOPHY 100/3.6 is insulin degludec; liraglutide. There are forty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the insulin degludec; liraglutide profile page.
When can HUMALOG KWIKPEN (insulin lispro recombinant) generic drug versions launch?
Generic name: insulin lispro recombinant
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 12, 2023
Generic Entry Controlled by: Norway Patent 20,061,150
HUMALOG KWIKPEN is a drug marketed by
This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering HUMALOG KWIKPEN
See drug price trends for HUMALOG KWIKPEN.
The generic ingredient in HUMALOG KWIKPEN is insulin lispro recombinant. There are forty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the insulin lispro recombinant profile page.
When can HUMALOG KWIKPEN (insulin lispro recombinant) generic drug versions launch?
Generic name: insulin lispro recombinant
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 12, 2023
Generic Entry Controlled by: Norway Patent 338,195
HUMALOG KWIKPEN is a drug marketed by
This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering HUMALOG KWIKPEN
See drug price trends for HUMALOG KWIKPEN.
The generic ingredient in HUMALOG KWIKPEN is insulin lispro recombinant. There are forty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the insulin lispro recombinant profile page.
When can HUMALOG MIX 50/50 KWIKPEN (insulin lispro protamine recombinant; insulin lispro recombinant) generic drug versions launch?
Generic name: insulin lispro protamine recombinant; insulin lispro recombinant
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 12, 2023
Generic Entry Controlled by: Norway Patent 20,061,150
HUMALOG MIX 50/50 KWIKPEN is a drug marketed by
This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering HUMALOG MIX 50/50 KWIKPEN
The generic ingredient in HUMALOG MIX 50/50 KWIKPEN is insulin lispro protamine recombinant; insulin lispro recombinant. There are forty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the insulin lispro protamine recombinant; insulin lispro recombinant profile page.
When can HUMALOG MIX 50/50 KWIKPEN (insulin lispro protamine recombinant; insulin lispro recombinant) generic drug versions launch?
Generic name: insulin lispro protamine recombinant; insulin lispro recombinant
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 12, 2023
Generic Entry Controlled by: Norway Patent 338,195
HUMALOG MIX 50/50 KWIKPEN is a drug marketed by
This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering HUMALOG MIX 50/50 KWIKPEN
The generic ingredient in HUMALOG MIX 50/50 KWIKPEN is insulin lispro protamine recombinant; insulin lispro recombinant. There are forty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the insulin lispro protamine recombinant; insulin lispro recombinant profile page.
When can HUMALOG MIX 75/25 KWIKPEN (insulin lispro protamine recombinant; insulin lispro recombinant) generic drug versions launch?
Generic name: insulin lispro protamine recombinant; insulin lispro recombinant
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 12, 2023
Generic Entry Controlled by: Norway Patent 20,061,150
HUMALOG MIX 75/25 KWIKPEN is a drug marketed by
This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering HUMALOG MIX 75/25 KWIKPEN
The generic ingredient in HUMALOG MIX 75/25 KWIKPEN is insulin lispro protamine recombinant; insulin lispro recombinant. There are forty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the insulin lispro protamine recombinant; insulin lispro recombinant profile page.
When can HUMALOG MIX 75/25 KWIKPEN (insulin lispro protamine recombinant; insulin lispro recombinant) generic drug versions launch?
Generic name: insulin lispro protamine recombinant; insulin lispro recombinant
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 12, 2023
Generic Entry Controlled by: Norway Patent 338,195
HUMALOG MIX 75/25 KWIKPEN is a drug marketed by
This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering HUMALOG MIX 75/25 KWIKPEN
The generic ingredient in HUMALOG MIX 75/25 KWIKPEN is insulin lispro protamine recombinant; insulin lispro recombinant. There are forty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the insulin lispro protamine recombinant; insulin lispro recombinant profile page.
When can HUMULIN 70/30 (insulin recombinant human; insulin susp isophane recombinant human) generic drug versions launch?
Generic name: insulin recombinant human; insulin susp isophane recombinant human
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 12, 2023
Generic Entry Controlled by: Norway Patent 20,061,150
HUMULIN 70/30 is a drug marketed by
This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering HUMULIN 70/30
The generic ingredient in HUMULIN 70/30 is insulin recombinant human; insulin susp isophane recombinant human. There are forty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the insulin recombinant human; insulin susp isophane recombinant human profile page.
When can HUMULIN 70/30 (insulin recombinant human; insulin susp isophane recombinant human) generic drug versions launch?
Generic name: insulin recombinant human; insulin susp isophane recombinant human
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 12, 2023
Generic Entry Controlled by: Norway Patent 338,195
HUMULIN 70/30 is a drug marketed by
This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering HUMULIN 70/30
The generic ingredient in HUMULIN 70/30 is insulin recombinant human; insulin susp isophane recombinant human. There are forty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the insulin recombinant human; insulin susp isophane recombinant human profile page.
When can HUMULIN N (insulin susp isophane recombinant human) generic drug versions launch?
Generic name: insulin susp isophane recombinant human
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 12, 2023
Generic Entry Controlled by: Norway Patent 20,061,150
This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering HUMULIN N
See drug price trends for HUMULIN N.
The generic ingredient in HUMULIN N is insulin susp isophane recombinant human. There are forty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the insulin susp isophane recombinant human profile page.
When can HUMULIN N (insulin susp isophane recombinant human) generic drug versions launch?
Generic name: insulin susp isophane recombinant human
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 12, 2023
Generic Entry Controlled by: Norway Patent 338,195
This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering HUMULIN N
See drug price trends for HUMULIN N.
The generic ingredient in HUMULIN N is insulin susp isophane recombinant human. There are forty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the insulin susp isophane recombinant human profile page.
When can HUMULIN R (insulin human) generic drug versions launch?
Generic name: insulin human
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 12, 2023
Generic Entry Controlled by: Norway Patent 20,061,150
This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering HUMULIN R
See drug price trends for HUMULIN R.
The generic ingredient in HUMULIN R is insulin human. There are forty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the insulin human profile page.
When can HUMULIN R (insulin human) generic drug versions launch?
Generic name: insulin human
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 12, 2023
Generic Entry Controlled by: Norway Patent 338,195
This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering HUMULIN R
See drug price trends for HUMULIN R.
The generic ingredient in HUMULIN R is insulin human. There are forty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the insulin human profile page.
When can PRADAXA (dabigatran etexilate mesylate) generic drug versions launch?
Generic name: dabigatran etexilate mesylate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 29, 2023
Generic Entry Controlled by: Norway Patent 20,061,420
This drug has two hundred and sixty-eight patent family members in fifty-two countries. There has been litigation on patents covering PRADAXA
See drug price trends for PRADAXA.
The generic ingredient in PRADAXA is dabigatran etexilate mesylate. There are twenty-six drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the dabigatran etexilate mesylate profile page.
When can PRADAXA (dabigatran etexilate mesylate) generic drug versions launch?
Generic name: dabigatran etexilate mesylate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 29, 2023
Generic Entry Controlled by: Norway Patent 20,130,778
This drug has two hundred and sixty-eight patent family members in fifty-two countries. There has been litigation on patents covering PRADAXA
See drug price trends for PRADAXA.
The generic ingredient in PRADAXA is dabigatran etexilate mesylate. There are twenty-six drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the dabigatran etexilate mesylate profile page.
When can PRADAXA (dabigatran etexilate mesylate) generic drug versions launch?
Generic name: dabigatran etexilate mesylate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 29, 2023
Generic Entry Controlled by: Norway Patent 334,115
This drug has two hundred and sixty-eight patent family members in fifty-two countries. There has been litigation on patents covering PRADAXA
See drug price trends for PRADAXA.
The generic ingredient in PRADAXA is dabigatran etexilate mesylate. There are twenty-six drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the dabigatran etexilate mesylate profile page.
When can JEVTANA KIT (cabazitaxel) generic drug versions launch?
Generic name: cabazitaxel
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: September 19, 2023
Generic Entry Controlled by: Norway Patent 20,061,714
JEVTANA KIT is a drug marketed by Sanofi Aventis Us. There are four patents protecting this drug. Two tentatively approved generics are ready to enter the market.
This drug has ninety-six patent family members in forty-six countries. There has been litigation on patents covering JEVTANA KIT
The generic ingredient in JEVTANA KIT is cabazitaxel. There are thirteen drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the cabazitaxel profile page.
When can JEVTANA KIT (cabazitaxel) generic drug versions launch?
Generic name: cabazitaxel
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: September 19, 2023
Generic Entry Controlled by: Norway Patent 2,015,013
JEVTANA KIT is a drug marketed by Sanofi Aventis Us. There are four patents protecting this drug. Two tentatively approved generics are ready to enter the market.
This drug has ninety-six patent family members in forty-six countries. There has been litigation on patents covering JEVTANA KIT
The generic ingredient in JEVTANA KIT is cabazitaxel. There are thirteen drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the cabazitaxel profile page.
When can JEVTANA KIT (cabazitaxel) generic drug versions launch?
Generic name: cabazitaxel
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: September 19, 2023
Generic Entry Controlled by: Norway Patent 335,997
JEVTANA KIT is a drug marketed by Sanofi Aventis Us. There are four patents protecting this drug. Two tentatively approved generics are ready to enter the market.
This drug has ninety-six patent family members in forty-six countries. There has been litigation on patents covering JEVTANA KIT
The generic ingredient in JEVTANA KIT is cabazitaxel. There are thirteen drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the cabazitaxel profile page.
When can DUETACT (glimepiride; pioglitazone hydrochloride) generic drug versions launch?
Generic name: glimepiride; pioglitazone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 31, 2023
Generic Entry Controlled by: Norway Patent 20,062,515
DUETACT is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug and one Paragraph IV challenge.
This drug has fifty-nine patent family members in thirty-one countries. There has been litigation on patents covering DUETACT
See drug price trends for DUETACT.
The generic ingredient in DUETACT is glimepiride; pioglitazone hydrochloride. There are sixteen drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the glimepiride; pioglitazone hydrochloride profile page.
When can DUETACT (glimepiride; pioglitazone hydrochloride) generic drug versions launch?
Generic name: glimepiride; pioglitazone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 31, 2023
Generic Entry Controlled by: Norway Patent 340,294
DUETACT is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug and one Paragraph IV challenge.
This drug has fifty-nine patent family members in thirty-one countries. There has been litigation on patents covering DUETACT
See drug price trends for DUETACT.
The generic ingredient in DUETACT is glimepiride; pioglitazone hydrochloride. There are sixteen drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the glimepiride; pioglitazone hydrochloride profile page.
When can XARELTO (rivaroxaban) generic drug versions launch?
Generic name: rivaroxaban
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2023
Generic Entry Controlled by: Norway Patent 20,062,942
This drug has one hundred and fifty-six patent family members in forty-seven countries. There has been litigation on patents covering XARELTO
See drug price trends for XARELTO.
The generic ingredient in XARELTO is rivaroxaban. There are thirty-five drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the rivaroxaban profile page.
When can XARELTO (rivaroxaban) generic drug versions launch?
Generic name: rivaroxaban
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2023
Generic Entry Controlled by: Norway Patent 340,156
This drug has one hundred and fifty-six patent family members in forty-seven countries. There has been litigation on patents covering XARELTO
See drug price trends for XARELTO.
The generic ingredient in XARELTO is rivaroxaban. There are thirty-five drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the rivaroxaban profile page.
When can VYZULTA (latanoprostene bunod) generic drug versions launch?
Generic name: latanoprostene bunod
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 05, 2024
Generic Entry Controlled by: Norway Patent 20,063,567
This drug has fifty-three patent family members in thirty-eight countries.
See drug price trends for VYZULTA.
The generic ingredient in VYZULTA is latanoprostene bunod. One supplier is listed for this generic product. Additional details are available on the latanoprostene bunod profile page.
When can VYZULTA (latanoprostene bunod) generic drug versions launch?
Generic name: latanoprostene bunod
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 05, 2024
Generic Entry Controlled by: Norway Patent 20,151,341
Patent Title: Prostaglandinnitrooksyderivater
This drug has fifty-three patent family members in thirty-eight countries.
See drug price trends for VYZULTA.
The generic ingredient in VYZULTA is latanoprostene bunod. One supplier is listed for this generic product. Additional details are available on the latanoprostene bunod profile page.
When can VYZULTA (latanoprostene bunod) generic drug versions launch?
Generic name: latanoprostene bunod
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 05, 2024
Generic Entry Controlled by: Norway Patent 337,217
This drug has fifty-three patent family members in thirty-eight countries.
See drug price trends for VYZULTA.
The generic ingredient in VYZULTA is latanoprostene bunod. One supplier is listed for this generic product. Additional details are available on the latanoprostene bunod profile page.
When can VYZULTA (latanoprostene bunod) generic drug versions launch?
Generic name: latanoprostene bunod
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 05, 2024
Generic Entry Controlled by: Norway Patent 339,685
This drug has fifty-three patent family members in thirty-eight countries.
See drug price trends for VYZULTA.
The generic ingredient in VYZULTA is latanoprostene bunod. One supplier is listed for this generic product. Additional details are available on the latanoprostene bunod profile page.
When can ORKAMBI (ivacaftor; lumacaftor) generic drug versions launch?
Generic name: ivacaftor; lumacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 30, 2024
Generic Entry Controlled by: Norway Patent 20,082,674
ORKAMBI is a drug marketed by Vertex Pharms Inc. There are twenty patents protecting this drug.
This drug has four hundred and fifty patent family members in thirty-five countries.
See drug price trends for ORKAMBI.
The generic ingredient in ORKAMBI is ivacaftor; lumacaftor. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ivacaftor; lumacaftor profile page.
When can EPANOVA (omega-3-carboxylic acids) generic drug versions launch?
Generic name: omega-3-carboxylic acids
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 13, 2024
Generic Entry Controlled by: Norway Patent 20,064,146
EPANOVA is a drug marketed by Astrazeneca. There are seven patents protecting this drug.
This drug has eighty-four patent family members in forty countries.
The generic ingredient in EPANOVA is omega-3-carboxylic acids. There is one drug master file entry for this API. Additional details are available on the omega-3-carboxylic acids profile page.
When can EPANOVA (omega-3-carboxylic acids) generic drug versions launch?
Generic name: omega-3-carboxylic acids
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 13, 2024
Generic Entry Controlled by: Norway Patent 341,821
EPANOVA is a drug marketed by Astrazeneca. There are seven patents protecting this drug.
This drug has eighty-four patent family members in forty countries.
The generic ingredient in EPANOVA is omega-3-carboxylic acids. There is one drug master file entry for this API. Additional details are available on the omega-3-carboxylic acids profile page.
When can OSPHENA (ospemifene) generic drug versions launch?
Generic name: ospemifene
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 23, 2024
Generic Entry Controlled by: Norway Patent 20,064,262
This drug has ninety-four patent family members in thirty-one countries. There has been litigation on patents covering OSPHENA
See drug price trends for OSPHENA.
The generic ingredient in OSPHENA is ospemifene. There are six drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ospemifene profile page.
When can OSPHENA (ospemifene) generic drug versions launch?
Generic name: ospemifene
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 23, 2024
Generic Entry Controlled by: Norway Patent 341,573
This drug has ninety-four patent family members in thirty-one countries. There has been litigation on patents covering OSPHENA
See drug price trends for OSPHENA.
The generic ingredient in OSPHENA is ospemifene. There are six drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ospemifene profile page.
When can RUKOBIA (fostemsavir tromethamine) generic drug versions launch?
Generic name: fostemsavir tromethamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 15, 2024
Generic Entry Controlled by: Norway Patent 20,064,062
RUKOBIA is a drug marketed by Viiv Hlthcare. There are three patents protecting this drug.
This drug has thirty-nine patent family members in thirty countries.
See drug price trends for RUKOBIA.
The generic ingredient in RUKOBIA is fostemsavir tromethamine. One supplier is listed for this generic product. Additional details are available on the fostemsavir tromethamine profile page.
When can RUKOBIA (fostemsavir tromethamine) generic drug versions launch?
Generic name: fostemsavir tromethamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 15, 2024
Generic Entry Controlled by: Norway Patent 336,742
RUKOBIA is a drug marketed by Viiv Hlthcare. There are three patents protecting this drug.
This drug has thirty-nine patent family members in thirty countries.
See drug price trends for RUKOBIA.
The generic ingredient in RUKOBIA is fostemsavir tromethamine. One supplier is listed for this generic product. Additional details are available on the fostemsavir tromethamine profile page.
When can SYNJARDY (empagliflozin; metformin hydrochloride) generic drug versions launch?
Generic name: empagliflozin; metformin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 16, 2024
Generic Entry Controlled by: Norway Patent 20,064,201
This drug has one hundred and ninety-two patent family members in forty-four countries. There has been litigation on patents covering SYNJARDY
See drug price trends for SYNJARDY.
The generic ingredient in SYNJARDY is empagliflozin; metformin hydrochloride. There are twenty-two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the empagliflozin; metformin hydrochloride profile page.
When can SYNJARDY (empagliflozin; metformin hydrochloride) generic drug versions launch?
Generic name: empagliflozin; metformin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 16, 2024
Generic Entry Controlled by: Norway Patent 20,140,127
This drug has one hundred and ninety-two patent family members in forty-four countries. There has been litigation on patents covering SYNJARDY
See drug price trends for SYNJARDY.
The generic ingredient in SYNJARDY is empagliflozin; metformin hydrochloride. There are twenty-two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the empagliflozin; metformin hydrochloride profile page.
When can SYNJARDY (empagliflozin; metformin hydrochloride) generic drug versions launch?
Generic name: empagliflozin; metformin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 16, 2024
Generic Entry Controlled by: Norway Patent 2,014,028
This drug has one hundred and ninety-two patent family members in forty-four countries. There has been litigation on patents covering SYNJARDY
See drug price trends for SYNJARDY.
The generic ingredient in SYNJARDY is empagliflozin; metformin hydrochloride. There are twenty-two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the empagliflozin; metformin hydrochloride profile page.
When can SYNJARDY (empagliflozin; metformin hydrochloride) generic drug versions launch?
Generic name: empagliflozin; metformin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 16, 2024
Generic Entry Controlled by: Norway Patent 335,264
This drug has one hundred and ninety-two patent family members in forty-four countries. There has been litigation on patents covering SYNJARDY
See drug price trends for SYNJARDY.
The generic ingredient in SYNJARDY is empagliflozin; metformin hydrochloride. There are twenty-two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the empagliflozin; metformin hydrochloride profile page.
When can SYNJARDY XR (empagliflozin; metformin hydrochloride) generic drug versions launch?
Generic name: empagliflozin; metformin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 16, 2024
Generic Entry Controlled by: Norway Patent 20,064,201
This drug has one hundred and sixty-six patent family members in forty countries. There has been litigation on patents covering SYNJARDY XR
See drug price trends for SYNJARDY XR.
The generic ingredient in SYNJARDY XR is empagliflozin; metformin hydrochloride. There are twenty-two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the empagliflozin; metformin hydrochloride profile page.
When can SYNJARDY XR (empagliflozin; metformin hydrochloride) generic drug versions launch?
Generic name: empagliflozin; metformin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 16, 2024
Generic Entry Controlled by: Norway Patent 20,140,127
This drug has one hundred and sixty-six patent family members in forty countries. There has been litigation on patents covering SYNJARDY XR
See drug price trends for SYNJARDY XR.
The generic ingredient in SYNJARDY XR is empagliflozin; metformin hydrochloride. There are twenty-two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the empagliflozin; metformin hydrochloride profile page.
When can SYNJARDY XR (empagliflozin; metformin hydrochloride) generic drug versions launch?
Generic name: empagliflozin; metformin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 16, 2024
Generic Entry Controlled by: Norway Patent 2,014,028
This drug has one hundred and sixty-six patent family members in forty countries. There has been litigation on patents covering SYNJARDY XR
See drug price trends for SYNJARDY XR.
The generic ingredient in SYNJARDY XR is empagliflozin; metformin hydrochloride. There are twenty-two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the empagliflozin; metformin hydrochloride profile page.
When can SYNJARDY XR (empagliflozin; metformin hydrochloride) generic drug versions launch?
Generic name: empagliflozin; metformin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 16, 2024
Generic Entry Controlled by: Norway Patent 335,264
This drug has one hundred and sixty-six patent family members in forty countries. There has been litigation on patents covering SYNJARDY XR
See drug price trends for SYNJARDY XR.
The generic ingredient in SYNJARDY XR is empagliflozin; metformin hydrochloride. There are twenty-two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the empagliflozin; metformin hydrochloride profile page.
When can TEKTURNA (aliskiren hemifumarate) generic drug versions launch?
Generic name: aliskiren hemifumarate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 17, 2024
Generic Entry Controlled by: Norway Patent 20,064,670
This drug has forty patent family members in twenty-two countries. There has been litigation on patents covering TEKTURNA
See drug price trends for TEKTURNA.
The generic ingredient in TEKTURNA is aliskiren hemifumarate. There are four drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the aliskiren hemifumarate profile page.
When can TEKTURNA (aliskiren hemifumarate) generic drug versions launch?
Generic name: aliskiren hemifumarate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 17, 2024
Generic Entry Controlled by: Norway Patent 343,217
This drug has forty patent family members in twenty-two countries. There has been litigation on patents covering TEKTURNA
See drug price trends for TEKTURNA.
The generic ingredient in TEKTURNA is aliskiren hemifumarate. There are four drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the aliskiren hemifumarate profile page.
When can IMPLANON (etonogestrel) generic drug versions launch?
Generic name: etonogestrel
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 19, 2024
Generic Entry Controlled by: Norway Patent 20,064,716
IMPLANON is a drug marketed by Organon. There is one patent protecting this drug.
This drug has thirty-two patent family members in twenty-six countries.
The generic ingredient in IMPLANON is etonogestrel. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the etonogestrel profile page.
When can IMPLANON (etonogestrel) generic drug versions launch?
Generic name: etonogestrel
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 19, 2024
Generic Entry Controlled by: Norway Patent 338,191
IMPLANON is a drug marketed by Organon. There is one patent protecting this drug.
This drug has thirty-two patent family members in twenty-six countries.
The generic ingredient in IMPLANON is etonogestrel. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the etonogestrel profile page.
When can FORTEO (teriparatide recombinant human) generic drug versions launch?
Generic name: teriparatide recombinant human
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 30, 2024
Generic Entry Controlled by: Norway Patent 20,064,955
This drug has thirty-seven patent family members in twenty-five countries. There has been litigation on patents covering FORTEO
See drug price trends for FORTEO.
The generic ingredient in FORTEO is teriparatide recombinant human. There are four drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the teriparatide recombinant human profile page.
When can FORTEO (teriparatide recombinant human) generic drug versions launch?
Generic name: teriparatide recombinant human
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 30, 2024
Generic Entry Controlled by: Norway Patent 336,161
This drug has thirty-seven patent family members in twenty-five countries. There has been litigation on patents covering FORTEO
See drug price trends for FORTEO.
The generic ingredient in FORTEO is teriparatide recombinant human. There are four drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the teriparatide recombinant human profile page.
When can DUAVEE (bazedoxifene acetate; estrogens, conjugated) generic drug versions launch?
Generic name: